Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RNF114 | Q9Y508 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5241094 | 0.76 | P2RX4 (0.65) | NPC1MITFRAB9AP2RX4 | |
| SCHEMBL10953413 | 0.75 | P2RX4 (0.40) | NPC1MITFRAB9AP2RX4MAPT | |
| SCHEMBL30869494 | 0.71 | CUL4A (0.33) | CASP2NPC1AHRCUL4AMAPT | |
| SCHEMBL18216974 | 0.70 | P2RX4 (0.36) | NPC1MITFRAB9AP2RX4MAPT | |
| SCHEMBL7643900 | 0.70 | KMO (0.43) | AHRCUL4AMAPTMYCNR4A1 | |
| SCHEMBL30869661 | 0.70 | WNT1 (0.35) | CUL4A | |
| SCHEMBL24378120 | 0.68 | SIRT1 (0.47) | CASP2 | |
| SCHEMBL1929776 | 0.68 | P2RX4 (0.49) | NPC1MITFRAB9AP2RX4MAPT | |
| SCHEMBL31314363 | 0.67 | AHR (0.54) | CASP2AHRCUL4AMAPTMYC | |
| SCHEMBL31443280 | 0.67 | AHR (0.48) | AHRCUL4AMAPTSMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | CASP2 2914/4885NPC1 58/4885MITF 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.